| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8654b1e65e198c0b5ae2c0be5a99d7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e2448995bd8dd4bd1476f11d772246a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e42129b5c0488671889fe10ec04f45b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdd619b8a2cc2f110b9ee4dc8d896a17 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 |
| filingDate |
2007-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a363d52128ed0719dffb9ead0a21d34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0acce5a93efedcd36e397c6a852ca1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b920ee092a6ba13d7a51021a4b628df |
| publicationDate |
2009-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009014510-A1 |
| titleOfInvention |
Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| abstract |
The present invention relates to development of efficacious pharmaceutical ophthalmic compositions comprising a poorly water soluble active compound in a therapeutically effective amount and a polyethylene co-solvent in a suitable amount to treat or prevent diseases due to ocular neovascularization and enhanced vascular permeability. The composition is in the form of a gel, and the prefered active compound is the multi-targeted receptor tyrosine kinase' inhibitor N- [4- (3-amino-lH-indazol-4-yl) phenye] -N- (2-f luoro-5-methylphenye) urla] |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9707173-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015041294-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010221369-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102340991-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8912236-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010101992-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105362221-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013535451-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102340993-A |
| priorityDate |
2007-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |